Elanco launches Befrena as it expands canine dermatology push
Bottom line
Version 1
Elanco has begun a phased U.S. launch of Befrena (tirnovetmab), a new anti-IL-31 monoclonal antibody injection for dogs with allergic dermatitis and canine atopic dermatitis. The product was approved by the USDA on December 31, 2025, and Elanco announced the commercial launch on May 18, 2026, with select early-experience clinics already using it. Elanco is positioning Befrena as an in-clinic biologic that starts controlling itch within 24 hours and is dosed every six to eight weeks, expanding its dermatology portfolio alongside Zenrelia and adding another option in a market long dominated by lokivetmab. (elanco.com)
Why it matters: For veterinary professionals, Befrena adds another long-acting injectable option for managing pruritus tied to allergic and atopic dermatitis, with no age or weight restrictions noted in Elanco’s launch materials. That could matter for case selection, clinic workflow, adherence, and conversations with pet parents who struggle with daily oral therapy or delayed presentation of itchy dogs. It also signals Elanco’s broader push into companion-animal biologics, backed by a recently completed expansion of monoclonal antibody manufacturing capacity in Elwood, Kansas. (investor.elanco.com)
What to watch: Watch for broader clinic availability, real-world uptake versus established itch therapies, and whether post-launch experience clarifies where Befrena fits best in dermatology protocols. (investor.elanco.com)
Key facts
- Brand
- Befrena
- Generic name
- tirnovetmab
- Type
- Anti-IL-31 monoclonal antibody injection
- Indication
- Dogs with allergic dermatitis and canine atopic dermatitis
- USDA approval date
- December 31, 2025
- U.S. launch date
- May 18, 2026
- Dosing interval
- Every six to eight weeks
- Onset
- Starts controlling itch within 24 hours
- Launch status
- Phased U.S. launch with select early-experience clinics already using it
Version 2
Elanco is expanding its canine dermatology portfolio with the phased U.S. launch of Befrena (tirnovetmab), a USDA-approved anti-IL-31 monoclonal antibody for dogs with allergic dermatitis and canine atopic dermatitis. The company announced the launch on May 18, 2026, after receiving USDA approval on December 31, 2025, positioning Befrena as a long-acting, in-clinic injection for itch control in a large and competitive dermatology market. (investor.elanco.com)
The launch builds on Elanco’s recent dermatology momentum. In its approval announcement, the company said Befrena became its second dermatology product approved in less than 18 months, joining Zenrelia, an oral JAK inhibitor for canine allergic skin disease. Company filings also framed Befrena as one of Elanco’s key innovation drivers for 2026, and the product arrives as the company continues to build out its U.S. biologics platform. (elanco.com)
Key product details are central to Elanco’s positioning. According to the company, Befrena is indicated for treatment of canine allergic and atopic dermatitis, starts controlling itch within 24 hours, and is recommended at six- to eight-week dosing intervals. Elanco has also highlighted that the product has no age or weight restrictions in its launch materials and has explicitly compared its dosing interval with lokivetmab, the incumbent anti-IL-31 biologic in this category. USDA product listings confirm tirnovetmab as a licensed veterinary biologic for canine use. (investor.elanco.com)
The manufacturing story matters, too. Just days ago, Elanco announced completion of a 25,000-square-foot expansion at its Elwood, Kansas site, supported by a $150 million investment to increase monoclonal antibody production capacity. The company tied that capacity directly to expected demand for products including Befrena and Trutect, suggesting this launch is part of a larger strategy to scale companion-animal biologics, not a one-off product addition. (investor.elanco.com)
Industry commentary so far has been limited but generally favorable. A dvm360 Q&A on monoclonal antibodies in veterinary medicine described tirnovetmab as one of the newest USDA-approved mAb therapies and emphasized the appeal of targeted biologics in veterinary practice. Trade coverage from AAHA and Veterinary Practice News has similarly focused on Befrena’s role as a new in-clinic option for allergic itch relief in dogs, reinforcing that the launch is being watched as a meaningful addition to a familiar treatment category rather than a wholly new mechanism. (dvm360.com)
Why it matters: For veterinary teams, Befrena could widen the decision tree for canine pruritus cases where convenience, duration, and in-clinic administration shape adherence and outcomes. A six- to eight-week injectable may appeal in cases where pet parents have trouble with daily oral dosing, where rapid itch control is a priority, or where clinicians want another biologic option alongside existing anti-IL-31 therapy. It may also intensify competition in canine dermatology, which could affect stocking decisions, client education, and how practices differentiate between oral immunomodulators and injectable monoclonal antibodies. These are company-framed advantages, and broader independent real-world data will be important for understanding comparative performance in practice. (investor.elanco.com)
What to watch: Near term, the key questions are how quickly the phased launch expands beyond early-experience clinics, whether supply keeps pace with demand as Elanco scales manufacturing, and how veterinarians position Befrena against established options in first-line and follow-up dermatitis care. Over the next several quarters, expect closer attention to real-world response, repeat-use patterns, and whether Elanco’s dermatology portfolio strategy translates into measurable share gains in clinic. (investor.elanco.com)